Cargando…

Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience

Little is known about how the change from intravenous to subcutaneous vedolizumab in a real-life setting in inflammatory bowel disease patients on stable maintenance therapy affects clinical outcomes. We compared the data on vedolizumab serum trough concentration, efficacy, and safety prior to and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Oršić Frič, Vlasta, Borzan, Vladimir, Šahinović, Ines, Borzan, Andrej, Kurbel, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962491/
https://www.ncbi.nlm.nih.gov/pubmed/37259387
http://dx.doi.org/10.3390/ph16020239
_version_ 1784896018517590016
author Oršić Frič, Vlasta
Borzan, Vladimir
Šahinović, Ines
Borzan, Andrej
Kurbel, Sven
author_facet Oršić Frič, Vlasta
Borzan, Vladimir
Šahinović, Ines
Borzan, Andrej
Kurbel, Sven
author_sort Oršić Frič, Vlasta
collection PubMed
description Little is known about how the change from intravenous to subcutaneous vedolizumab in a real-life setting in inflammatory bowel disease patients on stable maintenance therapy affects clinical outcomes. We compared the data on vedolizumab serum trough concentration, efficacy, and safety prior to and six months after the switch from intravenous to subcutaneous vedolizumab. In total, 24 patients, 13 with ulcerative colitis (UC) and 11 with Crohn’s disease (CD), were included. Mean serum trough concentration of intravenous vedolizumab was significantly lower than mean serum trough concentration of subcutaneous vedolizumab (p = 0.002). There was no significant difference between C-reactive protein levels, fecal calprotectin levels or clinical scores (Harvey–Bradshaw index or Partial Mayo score) prior to transition to subcutaneous vedolizumab and after 6 months. In four (16.7%) patients, two CD and two UC, therapy was discontinued during the follow-up period with a median of 5 months (minimum–maximum: 4–6). In all patients, therapy was discontinued due to loss of response. In total, 13 adverse events were reported by 11 patients, and the most common adverse event was COVID-19. No serious adverse events were reported. In conclusion, subcutaneous vedolizumab has shown to be effective and safe in patients on previously established maintenance therapy with intravenous vedolizumab.
format Online
Article
Text
id pubmed-9962491
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99624912023-02-26 Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience Oršić Frič, Vlasta Borzan, Vladimir Šahinović, Ines Borzan, Andrej Kurbel, Sven Pharmaceuticals (Basel) Article Little is known about how the change from intravenous to subcutaneous vedolizumab in a real-life setting in inflammatory bowel disease patients on stable maintenance therapy affects clinical outcomes. We compared the data on vedolizumab serum trough concentration, efficacy, and safety prior to and six months after the switch from intravenous to subcutaneous vedolizumab. In total, 24 patients, 13 with ulcerative colitis (UC) and 11 with Crohn’s disease (CD), were included. Mean serum trough concentration of intravenous vedolizumab was significantly lower than mean serum trough concentration of subcutaneous vedolizumab (p = 0.002). There was no significant difference between C-reactive protein levels, fecal calprotectin levels or clinical scores (Harvey–Bradshaw index or Partial Mayo score) prior to transition to subcutaneous vedolizumab and after 6 months. In four (16.7%) patients, two CD and two UC, therapy was discontinued during the follow-up period with a median of 5 months (minimum–maximum: 4–6). In all patients, therapy was discontinued due to loss of response. In total, 13 adverse events were reported by 11 patients, and the most common adverse event was COVID-19. No serious adverse events were reported. In conclusion, subcutaneous vedolizumab has shown to be effective and safe in patients on previously established maintenance therapy with intravenous vedolizumab. MDPI 2023-02-05 /pmc/articles/PMC9962491/ /pubmed/37259387 http://dx.doi.org/10.3390/ph16020239 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Oršić Frič, Vlasta
Borzan, Vladimir
Šahinović, Ines
Borzan, Andrej
Kurbel, Sven
Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience
title Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience
title_full Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience
title_fullStr Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience
title_full_unstemmed Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience
title_short Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience
title_sort real-world study on vedolizumab serum concentration, efficacy, and safety after the transition from intravenous to subcutaneous vedolizumab in inflammatory bowel disease patients: single-center experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962491/
https://www.ncbi.nlm.nih.gov/pubmed/37259387
http://dx.doi.org/10.3390/ph16020239
work_keys_str_mv AT orsicfricvlasta realworldstudyonvedolizumabserumconcentrationefficacyandsafetyafterthetransitionfromintravenoustosubcutaneousvedolizumabininflammatoryboweldiseasepatientssinglecenterexperience
AT borzanvladimir realworldstudyonvedolizumabserumconcentrationefficacyandsafetyafterthetransitionfromintravenoustosubcutaneousvedolizumabininflammatoryboweldiseasepatientssinglecenterexperience
AT sahinovicines realworldstudyonvedolizumabserumconcentrationefficacyandsafetyafterthetransitionfromintravenoustosubcutaneousvedolizumabininflammatoryboweldiseasepatientssinglecenterexperience
AT borzanandrej realworldstudyonvedolizumabserumconcentrationefficacyandsafetyafterthetransitionfromintravenoustosubcutaneousvedolizumabininflammatoryboweldiseasepatientssinglecenterexperience
AT kurbelsven realworldstudyonvedolizumabserumconcentrationefficacyandsafetyafterthetransitionfromintravenoustosubcutaneousvedolizumabininflammatoryboweldiseasepatientssinglecenterexperience